

RESPONSE UNDER 37 CFR 1.116
EXAMINING PROCEDURE
EXAMINING GROUP 1623

PATENT

Rev 07/05

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
CENTRAL FAX CENTER
OCT 12 2006

In re application : Mitchell P. Fink et al.
Application No. : 10/659,063
Filed : September 10, 2003
Confirmation No. : 3827
For : EXTRACELLULAR NAD+ AND CADPR AS POTENT
ANTI-INFLAMMATORY AGENTS
Examiner : Henry, Michael C.
Attorney's Docket : UPIIT-008XX

TC Art Unit: 1623

I hereby certify that this correspondence is being sent via
facsimile to Examiner Michael C. Henry, TC Art Unit 1623, Fax No.
(571) 273 8300, on Oct. 12, 2006.

By: Holliday C. Heine
Holliday C. Heine, Ph.D.
Registration No. 34,346
Attorney for Applicant(s)

AMENDMENT PURSUANT TO 37 C.F.R. §1.116

Via Facsimile
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the final Office Action dated June 12, 2006,
in the above-identified patent application, please amended the
claims as follows.

WEISMAN, SCHUGEN,
CAGNON & LEBOVITZ LLP
TEL. (617) 542-2290
FAX. (617) 451-0313

Do
not
Enter
M.C.H.
11/20/06